Insight Resource Library Tap into Gubra’s vast production of publications, webinars, videos and posters to get the latest knowledge and insights within our focus areas: obesity, diabetes, MASH, CKD, IPF and IBD. Filtered (15) Filters Reset all × GAN ob/ob-MASH mouse × mPD95 × Obeticholic acid × Search × Resource type Data presentation (0) Poster (6) Publication (9) 3D imaging video (0) Webinar (0) Category × Disease model (212) Cardiovascular disease (10) AngII mouse (1) DIO-ApoE-KO mouse (1) DIO-LDLR-KO mouse (4) DIO-PCK9-AAV mouse (1) Isoprenaline-induced cardiomyopathy (1) Cholangiopathy (1) Bile duct ligation (BDL) mouse (1) Mdr2-KO mouse (1) CNS disease (39) Alzheimer's disease models (9) CNS activation (12) Drug distribution (6) Gene expression (1) Gene therapy (1) Parkinson's disease models (6) Diabetes (33) db/db mouse (17) Non-obese diabetic (NOD) mouse (4) ZDF rat (10) Inflammatory bowel disease (2) Acute DSS-IBD mouse (0) Chronic DSS-IBD mouse (2) Idiopathic pulmonary fibrosis (5) BLEO-IPF mouse (3) Chronic BLEO-IPF mouse (1) HFD-BLEO-IPF mouse (0) Kidney disease (31) Acute kidney injury (4) Bilateral ischemia reperfusion injury (bIRI) mouse (1) Unilateral ischemia reperfusion injury (uIRI) mouse (3) Chronic kidney disease (16) Anti-GBM glomerulonephritis mouse (1) Adenine diet-induced (ADI) nephropathy mouse (5) Polycystic kidney disease (PCK) rat (1) Unilateral ureteral obstruction (UUO) mouse (4) 5/6 nephrectomy (Nx) rat (2) Diabetic kidney disease (17) db/db-UNx mouse (1) ReninAAV UNx db/db mouse (11) ZSF-1 rat (0) Knock-out mouse models (8) Metabolic dysfunction-associated steatohepatitis (72) GAN DIO-MASH mouse (28) GAN DIO-MASH-HCC mouse (7) GAN ob/ob-MASH mouse (4) CDAA-HFD mouse (8) CDAA-HFD rat (9) AMLN DIO-MASH mouse (16) AMLN ob/ob-MASH mouse (12) Obesity (51) Bariatric surgery (10) DIO mouse (22) DIO rat (14) ob/ob mouse (8) Therapeutic Area (231) Alzheimer's disease (13) Alcoholic steatohepatitis (2) Cardiovascular disease (9) Chronic kidney disease (26) Cholangiopathy (1) Diabetes (55) Diabetic cardiomyopathy (2) Diabetic kidney disease (18) Hepatocellular carcinoma (5) Idiopathic pulmonary fibrosis (5) Inflammatory bowel disease (2) Metabolic dysfunction-associated steatohepatitis (80) Obesity (80) Parkinson's disease (8) Target (143) Alpha-synuclein (1) Autotaxin (1) Beta amyloid (4) Acetyl-CoA carboxylase (2) Amylin receptor (4) Angiotensin converting enzyme (ACE) (4) AMPK (1) ASBT (2) CB1 receptor (5) CCK receptor (4) D2 receptor (3) DPP-IV (2) Fatty acid synthase (1) FGF receptor-1 (3) FXR (12) GCC receptor (1) GFRAL (1) Ghrelin receptor (3) GIP receptor (4) GLP-1 receptor (71) GLP-2 receptor (5) Glucagon receptor (5) GPR119 (0) GPR120 (1) G-protein coupled receptor 10 (GPR10) (1) HSD17b13 (1) 5-HT2C receptor (3) IL-1beta receptor (1) Insulin receptor (2) mARC1 (1) MC4 receptor (4) Monoamine transporter (2) Leptin receptor (1) Neuropeptide FF receptor type 2 (1) Neurotensin receptor (1) Nicotinic acetylcholine receptor (1) NPY receptor (2) NMU receptor (2) PCSK9 (1) PICK1 (1) PPAR (22) PSD-95 (1) Renin–angiotensin system (3) Secretin receptor (1) SGLT-2 (5) TAAR1 (1) TGF-beta (5) TGR5 (2) THR-ß receptor (5) Y2 receptor (3) Compound (140) Aducanumab biosimilar (4) Adeno-associated virus (AAV)-mediated gene therapy (1) A3907 (2) Adrenomedullin (2) Alk5 inhibitor (4) ALT-801 (1) Amylin (3) Amylin receptor agonist (1) BLD-0409 (1) Bromocriptine (2) CHS-131 (1) Captopril (1) Cilofexor (1) Cotadutide (1) DA-1241 (1) Dapagliflozin (2) Dietary intervention (4) Exenatide (9) Elafibranor (9) Empagliflozin (4) Exendin-4 analogues (3) FGF21 (3) Firsocostat (2) GDF15 analogues (1) Ghrelin (1) GIP receptor agonist (1) GIPRA (1) GIP receptor antagonist (1) Glibenclamide (1) GLP-1 (5) GLP-1 receptor agonist (5) GLP-2 (1) Glucagon receptor agonist (1) Glucose-dependent insulinotropic polypeptide (GIP) (1) Guanylin (1) GUB06-046 (1) GUB08-248 (1) GUB09-123 (1) GUB09-145 (2) GUB08251 (1) GUB021794 (1) GUBamy (1) GS-834356 (1) HSD17b13 inhibitor (1) Icosabutate (1) ID166 (0) Insulin (1) INT-767 (4) INT-787 (0) Lanifibranor (9) LEAP-2 (2) Leptin (1) Linagliptin (5) Liraglutide (30) Lisinopril (4) Lorcaserin (3) MEDI0382 (1) mPD95 (1) Neuromedin U (2) Neurotensin (1) Neurturin (1) Nicotine (1) Obeticholic acid (10) Oxyntomodulin (1) PYY3-36 (4) Prolactin-releasing peptide (1) Resmetirom (6) Rimonabant (4) Rosiglitazone (2) S961 (1) Salmon calcitonin (1) SEFA-1024 (1) Seladelpar (2) Semaglutide (28) SER140 (1) Setmelanotide (3) Sibutramine (4) TAAR1 agonists (1) Taspoglutide (1) Teduglutide (2) TVB-3664 (1) UCCB01-147 (1) Uroguanylin (1) Y2 receptor agonist (1) ZP3022 (3) Method/Endpoint (253) 3D imaging (55) Adeno-associated virus (AAV)-mediated gene delivery (14) Atherosclerotic plaques (3) Beta-cell mass (12) Blood pressure (1) Body composition (11) Body weight (115) Blood biochemistry (77) Bariatric surgery (12) Bioinformatics (101) c-Fos activation (19) Clinical trial (2) Conditioned taste aversion test (1) Drug discovery (25) Drug distribution (11) Energy expenditure monitoring (4) Echocardiography (ECG) (3) Flow cytometry (1) Gut biopsy (6) Glomerular filtration rate (GFR) (7) Gastric emptying (3) Gut morphometry (11) Glucose-stimulated insulin secretion (GSIS) (1) Histopathology score (71) Heart morphometry (4) Intraperitoneal glucose tolerance test (IPGTT) (7) Image analysis (138) Immunohistochemistry (IHC) (136) In situ hybridization (ISH) (14) Insulin tolerance test (ITT) (2) Kidney biopsy (2) Kidney morphometry (22) Lung functional test (3) Light sheet fluorescence microscopy (LSFM) (58) Liver biopsy (64) Liver morphometry (62) Lung biochemistry (2) Laser-capture microdissection (LCM) (9) Magnetic resonance imaging (MRI) (2) Microbiomics (5) Micro-computed tomography (micro-CT) (1) Neurobehavior (6) Next-generation sequencing (44) Nephrectomy (14) Oral glucose tolerance test (OGTT) (20) Pancreatectomy (1) Peptide chemistry (14) Pharmacokinetics (9) Proteomics (1) qPCR (1) Real-time food intake/activity analysis (32) Receptor binding (3) Roux-en-Y gastric bypass (RYGB) (8) RNA sequencing (79) Single-cell RNA sequencing (3) Single-nucleus RNA sequencing (6) siRNA (1) StreaMLine (1) Surgery (12) Spirometry (3) Stereology (29) Stereotaxic injection (2) Ultrasound imaging (1) Urine biochemistry (12) Vasculature (2) Vertical sleeve gastrectomy (1) Western Blotting (1) Whole-body plethysmography (2) Whole-brain in situ hybridization (3) Species (207) Hamster (1) Human (28) Mouse (166) Minipig (2) Non-human primate (3) Pig (3) Rat (32) Show (15) Cancel Sort result Default sorting By title: alphabetical By title: reverse By date: oldest first By date: newest first Reset all × GAN ob/ob-MASH mouse × mPD95 × Obeticholic acid × 15 resource library items found PublicationIncreased hepatoprotective effects of the novel farnesoid X receptor agonist INT-787 versus obeticholic acid in a mouse model of nonalcoholic steatohepatitis PublicationTargeting postsynaptic glutamate receptor scaffolding proteins PSD-95 and PICK1 for obesity treatment PosterProphylactic and therapeutic effects of the dual FXR/TGR5 agonist INT-767 in the GAN diet-induced ob/ob mouse model of advanced MASH with progressive fibrosis PosterClinical translatability of the GAN diet-induced obese and biopsy-confirmed mouse model of MASH PosterPreclinical efficacy and clinical translatability of obeticholic acid in the GAN diet-induced obese and biopsy-confirmed mouse model of NASH PosterMetabolic, biochemical, histological, and transcriptomic effects of semaglutide in the GAN diet-induced and biopsy-confirmed ob/ob mouse model of NASH PosterA3907, a novel inhibitor of bile acid transport in the intestine and the kidney, improves markers of metabolic and hepatic pathology and reduces NAFLD activity score and fibrosis stage in a diet-induced and biopsy-confirmed mouse model of nonalcoholic steatohepatitis PublicationDual targeting of hepatic fibrosis and atherogenesis by icosabutate, an engineered eicosapentaenoic acid derivative PublicationResolution of NASH and hepatic fibrosis by the GLP-1R and GCGR dual-agonist cotadutide via modulating mitochondrial function and lipogenesis PosterObeticholic acid improves histological, biochemical and gene expression profiles in Gubra AMLN mice with diet-induced and biopsy-confirmed NASH PublicationTowards a standard diet-induced and biopsy-confirmed mouse model of non-alcoholic steatohepatitis: Impact of dietary fat source PublicationCombined obeticholic acid and elafibranor treatment promotes additive liver histological improvements in a diet-induced ob/ob mouse model of biopsy-confirmed NASH PublicationDisease progression and pharmacological intervention in a nutrient-deficient rat model of nonalcoholic steatohepatitis PublicationMetabolic and hepatic effects of liraglutide, obeticholic acid and elafbranor in diet-induced obese mouse models of biopsy-confrmed nonalcoholic steatohepatitis PublicationINT-767 improves histopathological features in a diet-induced ob/ob mouse model of biopsy-confirmed non-alcoholic steatohepatitis For further information Contact us Gubra Hørsholm Kongevej 11B 2970 Hørsholm Denmark +45 3152 2650